| Literature DB >> 24309403 |
Kwonil Jung1, Kelly A Scheuer2, Zhenwen Zhang2, Qiuhong Wang2, Linda J Saif3.
Abstract
The pathogenesis of GIII.2 bovine norovirus (BoNoV) is not well understood. Our study demonstrated persisting diarrhea and prolonged fecal shedding, but with a lack of significant intestinal lesions in gnotobiotic (Gn) calves infected with GIII.2 BoNoV, CV186-OH/00/US strain. Nine 4 to 7-day-old Angus/Jersey crossbred Gn calves were orally inoculated with 10.0-11.9 log10 genomic equivalents (GE)/calf of CV186-OH (n=7) or mock (n=2). Calves were euthanized at post-inoculation day (PID) 1 (n=1) when moderate to severe lethargy was observed and at PIDs 2-6 (n=4) after lethargy had subsided. Two calves were kept longer term (until PID 30) for monitoring fecal shedding patterns by TaqMan real-time RT-PCR (qRT-PCR). Most infected calves exhibited two clinical signs: (i) acute but persisting diarrhea and (ii) acute moderate to severe lethargy. The two infected calves, followed longer-term, had prolonged fecal viral RNA shedding [peak average titer of 11.8 (± 0.2) log10GE/ml] at least until PID 20. By qRT-PCR, 5 infected calves had low viral RNA titers in serum, ranging from 4.0 to 5.8 log10GE/ml, at PIDs 1-5, but not (<2.7 log10GE/ml) at PIDs 6-30. The latter observation coincided with the presence of serum IgG antibody to BoNoV at PIDs 8-30. Collectively, the GIII.2 BoNoV strain CV186-OH induced only mild enteropathogenicity, evident by the lack of significant intestinal lesions, but it led to persisting mild diarrhea and prolonged fecal virus shedding in Gn calves. The prolonged fecal shedding of GIII.2 BoNoV might partially explain how this virus is maintained as endemic infections in cattle.Entities:
Keywords: Cattle; Norovirus; Pathogenesis; Prolonged virus shedding
Mesh:
Substances:
Year: 2013 PMID: 24309403 PMCID: PMC3905316 DOI: 10.1016/j.vetmic.2013.11.008
Source DB: PubMed Journal: Vet Microbiol ISSN: 0378-1135 Impact factor: 3.293
Fig. 1Intermittent but persisting diarrhea and prolonged fecal viral RNA shedding of calves #3 and 4 infected with GIII.2 BoNoV, CV186-OH strain. Calves #3 and 4 were inoculated orally with lower doses (11.0–11.3 log10 GE) of the calf #1-passaged intestinal contents. They were monitored for longer-term clinical signs and virus shedding for PIDs 1–30 and PIDs 1–21, respectively. Fecal samples or rectal swabs were collected daily from each animal throughout the experiment. The BoNoV fecal shedding titers were determined by qRT-PCR, and each test was performed in triplicate. The dotted line indicates the detection limit (3.7 log10 GE/ml) of the qRT-PCR.
Virus RNA shedding determined by qRT-PCR in the feces of GIII.2 BoNoV (CV186-OH)-infected calves during the early stages of infection.
| Calf # | Calf age when inoculated | Inoculum titer (log10 GE/calf) | Viral titers (log10 GE/ml of rectal swab fluid or fecal sample) | PID when virus titer peaked | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Post-inoculation day (PID) | ||||||||||
| (day) | 0 | 1 | 2 | 3 | 4 | 5 | 6 | |||
| 1 | 6 | 11.9 | <3.7 | <3.7 | 9.9 | 10.6 | EU | ≥3 (ND | ||
| 2 | 5 | 11.9 | <3.7 | 10.1 | 9.7 | EU | 1 | |||
| 3 | 4 | 11.3 | <3.7 | 11.9 | 11.9 | 10.9 | 11.2 | 10.9 | 10.4 | 1 and 2 |
| 4 | 4 | 11.0 | <3.7 | 11.6 | 10.3 | 10.1 | 10.1 | 9.6 | 8.9 | 1 |
| 5 | 4 | 11.0 | <3.7 | 11.4 (EU) | ≥1 (ND) | |||||
| 6 | 7 | 10.0 | <3.7 | 10.7 | 10.1 | 10.4 | 8.7 | 8.8 | EU | 1 |
| 7 | 7 | 10.1 | <3.7 | <3.7 | 10.4 | 10.7 | 10.9 | EU | ≥4 (ND) | |
Real-time PCR-negative, <3.7 log10 GE/ml (detection limit of the qRT-PCR for rectal swab fluid or fecal sample).
Real-time PCR-positive, log10 viral titer (GE/ml of rectal swab fluid or fecal sample).
EU, euthanized.
ND, not determined.
Virus shedding of calves #3 and 4 monitored for longer-term (Fig. 1).
Detection of viral RNA by qRT-PCR and IgG antibody titers to BoNoV in serum samples.
| Calf # | PID (or age of negative control calf) | qRT-PCR results | Serum IgG antibody titers | ||||
|---|---|---|---|---|---|---|---|
| VLPs of GIII.2 BoNoV (CV186-OH) | VLPs of GII.4 HuNoV (HS194) | ||||||
| ELISA blocking solution A | ELISA blocking solution B | ELISA blocking solution A | ELISA blocking solution B | ||||
| 1 | 0 | − | (<2.7) | <4 | <4 | <4 | <4 |
| 4 | + | (4.1) | <4 | <4 | <4 | <4 | |
| 2 | 0 | − | (<2.7) | <4 | <4 | <4 | <4 |
| 3 | + | (4.0) | <4 | <4 | <4 | <4 | |
| 3 | 0 | − | (<2.7) | <4 | <4 | <4 | <4 |
| 2 | + | (4.1) | <4 | <4 | <4 | <4 | |
| 9 | − | (<2.7) | <4 | 1024 | <4 | <4 | |
| 30 | − | (<2.7) | 256 | 4096 | <4 | 256 | |
| 4 | 0 | − | (<2.7) | <4 | <4 | <4 | <4 |
| 8 | − | (<2.7) | <4 | 256 | <4 | <4 | |
| 21 | − | (<2.7) | 256 | 4096 | <4 | 64 | |
| 5 | 0 | − | (<2.7) | <4 | <4 | <4 | <4 |
| 1 | + | (5.8) | <4 | <4 | <4 | <4 | |
| 6 | 0 | − | (<2.7) | <4 | <4 | <4 | <4 |
| 6 | − | (<2.7) | <4 | <4 | <4 | <4 | |
| 7 | 0 | − | (<2.7) | <4 | <4 | <4 | <4 |
| 1 | − | (<2.7) | <4 | <4 | <4 | <4 | |
| 5 | + | (5.5) | <4 | <4 | <4 | <4 | |
| 8 | 13 | −(<2.7) | <4 | <4 | <4 | <4 | |
| 9 | 8 | −(<2.7) | <4 | <4 | <4 | <4 | |
+/−, real-time PCR-positive (viral RNA titers; log10 GE per serum sample) or negative (<2.7 log10 GE/ml; detection limit of the qRT-PCR for serum sample).
ELISA blocking solution A; 2% non-fat dry milk (NFDM), ELISA blocking solution B; 1× buffered solution of casein (Universal Blocking Reagent, Biogenex, CA).